SHIM
CORT icon

Stone House Investment Management’s Corcept Therapeutics CORT Stock Holding History

Stone House Investment Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.17K Buy
48
+11
+30% +$664 ﹤0.01% 593
2026
Q1 		$1.49K Buy
+37
New +$1.38K ﹤0.01% 643

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Stone House Investment Management's CORT Position: Q2 2026 in Review

Stone House Investment Management increased its Corcept Therapeutics (CORT) stake by 30% in Q2 2026, buying an estimated $664 and bringing the position to 48 shares worth $4.17K. The position accounts for ﹤0.01% of the portfolio, ranked #593.

Stone House Investment Management first reported a position in CORT in Q1 2026 and has held it in 2 quarters since. 423 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Stone House Investment Management held 48 shares of Corcept Therapeutics worth $4.17K as of Q2 2026.
  • Stone House Investment Management bought 11 Corcept Therapeutics shares in Q2 2026, an estimated $664.
  • Corcept Therapeutics made up ﹤0.01% of Stone House Investment Management's portfolio in Q2 2026, its #593 holding.
  • Stone House Investment Management first reported a position in Corcept Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 423 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Stone House Investment Management's 13F filing for Q2 2026, filed 5 Aug 2026.